What is Viridian Therapeutics, Inc.'s SG&A?

Viridian Therapeutics, Inc. (VRDN) reported SG&A of $38.68M in Q1 2026.

How has Viridian Therapeutics, Inc.'s SG&A changed year-over-year?

Viridian Therapeutics, Inc.'s SG&A increased by 126.2% year-over-year, from $17.1M to $38.68M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Viridian Therapeutics, Inc. VRDN SG&A

SG&A at other companies

AmgenAMGN

$1.6B-5.0%

ANI PharmaceuticalsANIP

$73.66M-3.8%

Syndax PharmaceuticalsSNDX

$44.92M+48.6%

Vir Biotechnology, Inc.VIR

$23.34M-2.5%

Ultragenyx PharmaceuticalRARE

$88M+1.1%

TG TherapeuticsTGTX

$88.22M+75.3%

Other financials

Income statement

See full

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Balance sheet

See full

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Cash flow

See full

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Valuation

See full

Market cap$1.91B+82.0%

Enterprise value$1.77B+85.0%

P/S26.9×-3,445×

Profitability

See full

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Returns & leverage

See full

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s SG&A?: Viridian Therapeutics, Inc. (VRDN) reported SG&A of $38.68M in Q1 2026.
How has Viridian Therapeutics, Inc.'s SG&A changed year-over-year?: Viridian Therapeutics, Inc.'s SG&A increased by 126.2% year-over-year, from $17.1M to $38.68M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.